FDA Pleases No One With Final Guidance On Naming of Biologicals and Biosimilars

Những quyển sách tương tự

• Conflicting Opinions Flood FDA on Its Proposal for Biosimilar Naming
  Bằng: Barlas, Stephen
  Được phát hành: (2016)
• FDA Advisory Committee Approval of First Biosimilar Leaves Questions Unanswered: Sandoz’s Filgrastim Faces Naming and Court Hurdles
  Bằng: Barlas, Stephen
  Được phát hành: (2015)
• FDA Finalizes Drug Communication Guidance: P&T Committees Can Receive Data Beyond the Drug Label
  Bằng: Barlas, Stephen
  Được phát hành: (2018)
• FDA Readies New Guidance and User Fee Program for Biosimilars: Drug interchangeability and user fees are contentious issues the FDA must resolve. Is the FDA up to the task?
  Bằng: BARLAS, STEPHEN
  Được phát hành: (2012)
• FDA Guidance on Biosimilar Interchangeability Elicits Diverse Views: Current and Potential Marketers Complain About Too-High Hurdles
  Bằng: Barlas, Stephen
  Được phát hành: (2017)